

AMERICAN MEDICAL ASSOCIATION ORGANIZED MEDICAL STAFF SECTION

Resolution: 9  
(I-24)

Introduced by: Matthew Vo, MD

Subject: The Need for Long-Term Study of Potential Side Effects of GIP & GLP-1 Medications

Referred to: OMSS Reference Committee  
(xxxx, MD, Chair)

---

1 Whereas, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) medications  
2 continue to be heavily advertised and touted as some kind of miracle drug for weight loss—  
3 besides their main indication as treatment for diabetes, there are limited studies on the potential  
4 side-effects—especially those involving the senior (65 years and older) population, such as  
5 muscle loss and bone density loss; and  
6

7 Whereas, the costs of these medications continue to be high and they can potentially cost the  
8 healthcare system a lot of money over the long run; and  
9

10 Whereas, there are no clear guidelines of how long patients should be taking these medications,  
11 which are meant to be long-term and potentially life-long weight management medications, and  
12 whether the weight loss will be maintained if patients ever want to come off them; and  
13

14 Whereas, there are no long-term studies of the potential side effects of these medications while  
15 many side effects have been seen; and  
16

17 Whereas, there are no current recommendations to better safeguard patients taking these  
18 medications and patients are not required to be monitored by qualified health professionals,  
19 such as obesity specialists, endocrinologists, or gastroenterologists, while taking these  
20 medications; therefore be it  
21

22 RESOLVED, that our American Medical Association advocates for more long-term studies to  
23 identify and better address the potential side-effects of gastric inhibitory polypeptide (GIP) and  
24 glucagon-like peptide-1 (GLP-1) receptor agonist medications, especially in the 65-year and  
25 older population (Directive to Take Action); and be it further  
26

27 RESOLVED, that our AMA advocates for close monitoring of patients taking GIP and GLP-1  
28 receptor agonist medications by qualified healthcare professionals (Directive to Take Action).  
29

Fiscal Note: (Assigned by HOD)

Received: 9/28/2024

## REFERENCES

1. Seino, Y, Fukushima, M., & Tabe, D. (2010). GIP and GLP-1, the two incretin hormones: Similarities and differences. *Journal of Diabetes Investigation*. 1:12, 8-23. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020673/>
2. FDA-approved label for Ozempic (Semaglutide): [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/209637s020s021lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf)
3. FDA-approved label for Zepbound (Tirzepatide): [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/217806s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf)
4. Cubanski, J, Neuman, T. & Sroczynski. (2024). A new use for Wegovy open the door to Medicare coverage for millions of people with obesity. *Kaiser Family Foundation Issue Brief*. <https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/>
5. Sodhi, M, Rezaeianzadeh, R., & Kezouh, A. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. *JAMA*. 330(18): 1795-1797. <https://jamanetwork.com/journals/jama/fullarticle/2810542>
6. Joshi, G.P, Abdelmalak, B.B., Weigel, W.A., Soriano, S.G., Harbell, M.W., Kuo, C.I., Stricker, P.A., Domino, K.B. (2023). American Society of Anesthesiologists consensus-based guidance on perioperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. *American Society of Anesthesiologists Press Release*: June 29, 2023. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative>
7. Niewijk, G. (2024). Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns. *University of Chicago Medicine Press Release*: May 30, 2024. <https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/2024/may/research-on-qlp-1-drugs>
8. Cassata, C. (2023). Ozempic can cause major loss of muscle mass and reduce bone density. *Healthline*: May 2, 2023. <https://www.healthline.com/health-news/ozempic-muscle-mass-loss>
9. Daniel, K. (2024). What older adults need to know before taking a GLP-1 like Ozempic. *Everyday Health*: May 17, 2024. <https://www.everydayhealth.com/obesity/what-older-adults-need-to-know-before-taking-a-qlp-1-like-ozempic/>

**RELEVANT AMA POLICY**

**N/A**